Results 11 to 20 of about 16,645 (269)

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma

Research and Practice in Thrombosis and Haemostasis, 2022
Introduction Edoxaban is the only anti‐Xa inhibitor metabolized in pharmacologically active moiety that could interfere with chromogenic anti‐Xa assays, especially in case of drug‐drug interactions or physiological disorders.
Romain Siriez, Halil Yildiz, Céline Bouvy, Hélène Haguet, Vincent Maloteau, Michaël Hardy, François Mullier, Jean‐Michel Dogné, Philippe Hainaut, Jonathan Douxfils   +9 more
doaj   +4 more sources

Managing patients taking edoxaban in dentistry [PDF]

Journal of Clinical and Experimental Dentistry, 2017
Anticoagulation therapy is used in several conditions to prevent or treat thromboembolism. A new group of oral anticoagulants with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent ...
Curto Aguilera, Adrián, Curto, Daniel, Sanchez, Jorge   +2 more
core   +5 more sources

Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation

Clinical and Applied Thrombosis/Hemostasis, 2020
Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use. As the main adverse event is bleeding, it is relevant whether edoxaban has additional effects on platelet function. We aimed to assess
Juraj Sokol MD, PhD, Frantisek Nehaj MD, Jela Ivankova RNDr, Michal Mokan MD, PhD, Lenka Lisa MD, PhD, Jana Zolkova RNDr, Lubica Vadelova RNDr, Marian Mokan Prof, MD, DSc, FRCP Edin, Jan Stasko Prof, MD, PhD   +8 more
doaj   +5 more sources

Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy [PDF]

Case Reports in Critical Care, 2016
Introduction. The main adverse effect of anticoagulant therapy is bleeding, and major bleeding, including intracranial, gastrointestinal, and retroperitoneal bleeding, has been reported as an adverse effect of edoxaban, a direct oral anticoagulant (DOAC).
Kenichi Nitta, Hiroshi Imamura, Akihiro Yashio, Satoko Kashima, Katsunori Mochizuki   +4 more
doaj   +3 more sources

Edoxaban in venous thromboembolism and stroke prevention: an appraisal

Vascular Health and Risk Management, 2016
Marco Proietti,1,2 Gregory YH Lip1,3 1University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK; 2Department of Internal Medicine and Medical Specialties, Sapienza-University of Rome, Rome, Italy; 3Aalborg Thrombosis ...
Proietti M, Lip GYH
doaj   +5 more sources

Edoxaban-induced enterocolitis: The first case report demonstrating distinct endoscopic and histological features. [PDF]

DEN Open
Abstract Direct oral anticoagulants (DOACs), including edoxaban, are widely used for stroke prevention in atrial fibrillation and venous thromboembolism. While gastrointestinal bleeding and diarrhea are recognized adverse effects, DOAC‐induced enterocolitis has not been established as a distinct clinical entity.
Endo K, Yamada J, Katayama T, Yoshino Y, Fukushi D, Koiwai A, Kogure T, Hirota M, Satoh K.   +8 more
europepmc   +2 more sources

Association Between Statins Use and Major Bleeding in Patients Using Direct Oral Anticoagulants for Atrial Fibrillation. [PDF]

Pharmacoepidemiol Drug Saf
ABSTRACT Background Direct oral anticoagulants (DOAC) were developed as an alternative to vitamin K antagonists in the treatment of NVAF. Statins are frequently prescribed drugs for the prevention of atherosclerotic cardiovascular disease. A potential interaction between DOACs and statins has been described, suggesting that their concomitant use may ...
de Burgos-González A, Cea-Soriano L, Huerta-Álvarez C.   +2 more
europepmc   +2 more sources

Edoxaban in cardiovascular disease management: Review [PDF]

British Journal of Clinical Pharmacology, 2021
In the past decade, direct oral anticoagulants (DOACs) have transformed the world of anti‐thrombotic therapy. Edoxaban is the most recently approved DOAC. Though intended for use primarily in stroke prevention, it has found applications in various other conditions including thromboembolic and peripheral arterial disease.
Sharanyah Srinivasan, Muhammad Ajmal, Cristina Pecci, Tom Lassar   +3 more
openalex   +3 more sources

Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation

Frontiers in Pharmacology, 2021
Background and Purpose: Edoxaban exposure varies across different ethnicities. The purpose of our study was to examine the risk factors associated with high or low edoxaban concentrations in Asian populations.Methods: Participants with atrial ...
Shin-Yi Lin, Shin-Yi Lin, Ching-Hua Kuo, Li-Ting Ho, Yen-Bin Liu, Chih-Fen Huang, Chih-Fen Huang, Sung-Chun Tang, Jiann-Shing Jeng   +8 more
doaj   +1 more source

Unsolved issues of The Efficacy and Safety of Edoxaban

The Anatolian Journal of Cardiology, 2021
Leszek Drabik, Anetta Undas
openalex   +7 more sources